Showing results (281-290 of 350) with videos related to
Sort By:
Pageof 35
Acta Dermato-Venereologica|May 16, 2002
Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodiesA Parodi, M Caproni, A V Marzano, et al.Blood|May 9, 2001
Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice)A M Vannucchi, L Bianchi, C Cellai, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 21, 2018
Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosusA Verdelli, A Coi, A V Marzano, et al.Current Medicinal Chemistry|June 22, 2006
Antiviral and immunomodulatory properties of new pro-glutathione (GSH) moleculesA Fraternale, M F Paoletti, A Casabianca, et al.Expert Opinion on Biological Therapy|February 12, 2020
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literatureG Caldarola, F Pirro, A Di Stefani, et al.Scientific Reports|August 1, 2020
Precision-based exercise as a new therapeutic option for children and adolescents with haematological malignanciesFrancesca Lanfranconi, W Zardo, T Moriggi, et al.Expert Opinion on Biological Therapy|March 17, 2023
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year studyGiacomo Caldarola, A Chiricozzi, M Megna, et al.Journal of Photochemistry and Photobiology. B, Biology|May 22, 1998
Estimation of the effect of increasing UVB exposure on the human immune system and related resistance to infectious diseases and tumoursJ Garssen, M Norval, A el-Ghorr, et al.Frontiers in Immunology|January 30, 2023
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosisC Caruso, L Laterza, C R Settanni, et al.The British Journal of Dermatology|October 5, 2021
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trialM Goebeler, Z Bata-Csörgő, C De Simone, et al.Pageof 35